Holen Sie sich die Stockscreener-App
117.17
1.24%
-1.47
Vorhandelsmarkt:
118.25
1.08
+0.92%
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines declines to comment on M&A speculation at conference - MSN
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - MSN
Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating - TipRanks
Revolution Medicines CEO Addresses Investor Questions on Merck Acquisition at J.P. Morgan Healthcare Conference - geneonline.com
Revolution Medicines stock gains as Stifel highlights strong PDAC position By Investing.com - Investing.com India
Revolution Medicines stock gains as Stifel highlights strong PDAC position - Investing.com
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective - GuruFocus
$30B ‘might not be enough’ for Revolution Medicines, says Stifel - TipRanks
With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition - statnews.com
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Ru - GuruFocus
RVMD Projects Significant Growth with Solid Financial Position b - GuruFocus
Revolution Medicines (RVMD) CEO Cancels Conference Appearance - GuruFocus
RVMD: Late-stage RAS-targeted therapies advance, with new resistance-overcoming drugs entering trials in 2026 - TradingView — Track All Markets
Revolution Medicines CEO says not commenting on ‘rumors or speculation’ - TipRanks
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus - TechStock²
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - sharewise.com
Tema Etfs LLC Has $5.93 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Pharmaceutical Giants Eye Revolution Medicines with $23 Billion Market Cap Amid Oncology M&A Surge - geneonline.com
Revolution Medicines: Take The Win And Sell Following Large Move Sparked By Buyout Rumors - Seeking Alpha
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree - Pharmaceutical Technology
Merck Could Strike 30 Billion Deal for Revolution Medicines - Oncodaily
Merck in Talks to Acquire Revolution Medicines for Approximately $30 Billion - Intellectia AI
RVMD stock hits a record high on rumored takeover interest - MSN
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
AbbVie in advanced talks to buy cancer drugmaker Revolution Medicines, shares jump nearly 30% - MSN
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines - GuruFocus
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Finviz
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK - TechStock²
Erasca Stock Surges as Market Eyes Revolution Medicines Acquisition - StocksToTrade
A Look At Revolution Medicines (RVMD) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Revolution Medicines shares climb after FDA grants Orphan Drug Designation for pancreatic cancer treatment - MSN
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday - TechStock²
Revolution Medicines gains breakthrough therapy status for zoldonrasib - MSN
Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent 50% Weekly Surge? - Yahoo Finance
Merck in talks to buy Revolution Medicines: Report - Pharmacy Business
Revolution Medicines price target raised to $147 from $80 at Wedbush - TipRanks
Merck in Talks to Buy Revolution Medicines Per Financial Times Report - The Globe and Mail
How Revolution Medicines Inc. stock valuations compare to rivalsJuly 2025 Technicals & Proven Capital Preservation Methods - ulpravda.ru
Why Revolution Medicines stock surged by 11% today - MSN
Merck Looks To Buy Cancer Drugmaker Revolution Medicines As Keytruda Nears Patent Expiry: Report - Stocktwits
Why Revolution Medicines Stock Surged by 11% Today - sharewise.com
Revolution Medicines Soars Amid AbbVie Acquisition Talks - StocksToTrade
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus - TechStock²
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next - TechStock²
RVMD Stock Soars 11% After Reports Of Near $30B Buyout Talks With Merck - Stocktwits
Insider Sell: Jack Anders Sells 10,000 Shares of Revolution Medi - GuruFocus
Revolution Medicines jumps on report AbbVie nears takeover - MSN
Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 10,000 Shares - MarketBeat
Margaret Horn Sells 75,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod - TechStock²
Revolution Medicines Executives Sell Shares - TradingView — Track All Markets
Revolution Medicines’ Stock Run Leaves Little Room For Mistakes - Finimize
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD) for $30 Billion - GuruFocus
Merck Reportedly in Talks to Acquire Revolution Medicines (RVMD) - GuruFocus
Revolution Medicines stock soars on report of AbbVie takeover - MSN
STAT’s Adam Feuerstein says Revolution Medicines canceled meeting - TipRanks
Key facts: Merck in talks to acquire Revolution Medicines; seeks data on child vaccines - TradingView — Track All Markets
Merck in Talks to Buy Revolution Medicines for Around $30 Billion - The Wall Street Journal
Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle (RVMD) - Seeking Alpha
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark - TechStock²
Revolution Medicines stock soars. Takeover buzz grows, another suitor emerges. - MSN
0.90%
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):